[{"id":"5680e6c0-6a5a-4e90-aaac-028889578a1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05141253","created_at":"2021-12-02T18:54:25.304Z","updated_at":"2024-07-02T16:36:11.366Z","phase":"Phase 1","brief_title":"Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors","source_id_and_acronym":"NCT05141253","lead_sponsor":"Tongji Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RD133"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 01/12/2022","start_date":" 01/12/2022","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 11/01/2036","study_completion_date":" 11/01/2036","last_update_posted":"2022-04-27"},{"id":"2d23aab4-1f16-4ace-937a-0b431ccf7367","acronym":"","url":"https://clinicaltrials.gov/study/NCT05166070","created_at":"2021-12-21T15:53:43.976Z","updated_at":"2024-07-02T16:36:19.299Z","phase":"Phase 1","brief_title":"An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors","source_id_and_acronym":"NCT05166070","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RD133"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 01/01/2037","study_completion_date":" 01/01/2037","last_update_posted":"2021-12-21"}]